Insulin is a potent regulator of Sp1 transcription factor. To examine if glucagon, which usually antagonizes insulin, regulates Sp1, we assessed the levels of Sp1 by Western blotting from H-411E cells exposed to glucagon with or without insulin. Glucagon alone (1.5 ؋ 10 ؊9 to 1.5 ؋ 10 ؊5 M) stimulated Sp1 accumulation but inhibited insulin's (10,000 U/ml) stimulatory effect on Sp1. We also assessed the effect of TNF-␣, wortmannin, a PI3K inhibitor, and cAMP-dependent protein kinase inhibitor on Sp1 accumulation. While TNF-␣ (5 ng/ml) blocked insulin-stimulated Sp1, it failed to block stimulation of Sp1 by glucagon (1.5 ؋ 10 ؊5 M). Similarly, wortmannin inhibited insulin-but not glucagon-stimulated Sp1, whereas protein kinase inhibitor had an opposite effect. Thus, insulin acts primarily via PI3K, and glucagon apparently stimulates through a cAMP-dependent pathway. Insulin increased the staining intensity of Sp1 seen exclusively in the nuclei of H-411E cells. Sp1 was demonstrable in both nucleus and cytoplasm after glucagon treatment. I NSULIN HAS A broad range of physiological actions and plays a major role in diabetes mellitus. Despite much research, the signal transduction pathways involved in insulin action have not been completely elucidated (1). Past studies from our laboratories have shown reduced amount and activity of calmodulin (CaM), and low Km cAMP phosphodiesterase (PDE) activity in tissues from diabetic rats. Treatments with insulin restored these activities to normal (1a-3). Extension of these studies with a minimal deviant rat hepatoma cell line (H-411E) showed that CaM gene transcription is regulated by insulin (4). Furthermore, we found an obligatory role for the transcription factor Sp1 in both basal and insulin stimulated CaM gene expression (5). A key role for Sp1 in CaM gene transcription has been demonstrated by DNase I foot-printing, EMSA, Western blot, and transfection experiments (6 -8).
I
NSULIN HAS A broad range of physiological actions and plays a major role in diabetes mellitus. Despite much research, the signal transduction pathways involved in insulin action have not been completely elucidated (1) . Past studies from our laboratories have shown reduced amount and activity of calmodulin (CaM), and low Km cAMP phosphodiesterase (PDE) activity in tissues from diabetic rats. Treatments with insulin restored these activities to normal (1a-3) . Extension of these studies with a minimal deviant rat hepatoma cell line (H-411E) showed that CaM gene transcription is regulated by insulin (4) . Furthermore, we found an obligatory role for the transcription factor Sp1 in both basal and insulin stimulated CaM gene expression (5) . A key role for Sp1 in CaM gene transcription has been demonstrated by DNase I foot-printing, EMSA, Western blot, and transfection experiments (6 -8) .
The interrelationship between insulin and Sp1 and its role in CaM gene expression lead us to consider the role of glucagon in this system. Glucagon opposes insulin in most physiologic settings. Glucagon binds to a cell surface receptor and initiates its effects, primarily through cAMP-dependent mechanisms. For example, insulin and glucagon oppose each other in the maintenance of blood glucose concentrations. Similarly, glucagon raises intracellular cAMP, whereas insulin lowers it profoundly (9) . Although insulin deficiency remains the physiologic hallmark of diabetes, it is thought that the remaining unopposed actions of glucagon contribute significantly to the diabetic state by elevating the blood glucose and triggering both lipolysis and ketosis through cAMPmediated processes (9, 10) . High circulating plasma glucagon and cAMP levels are associated with diabetic ketoacidosis. Considering the critical role of both hormones in the diabetic process, we decided to systematically examine the regulation of Sp1 in response to insulin and glucagon, alone and together, and try to elucidate mechanisms involved.
experiments were repeated at least three times. At the end of the experimental treatments, total protein was extracted from the cells as described previously (7, 8) . Briefly, cells were washed twice with phosphate buffer, and RIPA buffer [1ϫ phosphate buffer, 1% igepal CA-230 (Sigma), 0.5% sodium deoxycholate, 0.1% SDS], 0.5 mm phenylmethylsulfonyl fluoride, 0.5 mm dithiothreitol, 1.0 mm sodium orthovanadate, aprotinin, and protease inhibitor cocktail was added. Cells were scraped and collected into an Eppendorf tube (Brinkman, Westbury, CT) and passed through a 21G needle to disrupt the cells and the resultant material homogenized. This procedure was conducted over ice. Extracts were further kept on ice for 30 -60 min and centrifuged at 10,000 ϫ g for 10 min. The supernatant was collected and protein quantitated, using Bio-Rad Laboratories, Inc. protein assay.
For immunoprecipitation reaction, 500 g of protein were added to 4 g of anti Sp1 antibodies in binding buffer (10 mm Tris HCl, pH 7.9, 2 mm MgCl 2 , 0.15 mm NaCl, 1 mm dithiothreitol, 10% glycerol, and 1 mm phenylmethylsulfonyl fluoride) at a final concentration of 1 g of protein per l and incubated at 4 C overnight. Protein A-Sepharose was then added and the mixture was incubated at 4 C on a rocker platform for 2 h. The antibody-protein A complexes were pelleted by centrifugation (1,000 ϫ g) and washed four times with binding buffer. The pellets were resuspended in 1ϫ SDS sample buffer, boiled and analyzed by SDS-PAGE (7, 8) .
Proteins from the above procedures were separated using 7.5% SDS-PAGE, loading equal amounts of protein from each sample. After electrophoresis, the protein was transferred to a Immobilon-P transfer membrane (Millipore Corp., Bedford, MA) using a Trans-Blot electrophoretic transfer cell (Bio-Rad Laboratories, Inc.). Western-blot analyses were conducted using either rabbit polyclonal anti-Sp1 antibody (1:5000) or monoclonal anti-O-linked GlcNAc antibody (1:1000). Chemiluminescent signal was developed using detection reagents from an enhanced chemiluminescence kit (ECL Plus, Amersham Pharmacia Biotech, Piscataway, NJ) and exposed to x-ray film to obtain the signal. The blots probed with anti-GlcNAc antibody were stripped and reprobed with anti-Sp1 antibody to confirm the presence of Sp1 protein and to validate that equal amounts of total protein were loaded in each lane. The other blots were stripped and probed again with antiactin antibody (1:10,000) to validate the equivalent loading of proteins in each lane. After analysis of the individual gels for Sp1, data from these experiments were collected and statistical analysis performed with reference to actin controls.
Dose-and time-response studies
Quiescent, 70 -80% confluent, H-411E cells were treated overnight (12-16 h ) with different doses of insulin and glucagon. Insulin doses were 100, 1,000, 10,000, and 100,000 U/ml, whereas glucagon doses were 1.5 ϫ 10 Ϫ9 , 1.5 ϫ 10 Ϫ8 , 1.5 ϫ 10 Ϫ7 , 1.5 ϫ 10 Ϫ6 , 1.5 ϫ 10 Ϫ5 m. Another study was conducted with 10,000 U/ml (0.06 mol/liter) insulin together with each glucagon dose. Insulin time-response studies were conducted at 1, 2, 4, and 6 h using 10,000 U/ml.
Signaling pathway studies with inhibitors
Several experiments were conducted with quiescent H-411E cells exposed to selected inhibitors. Cell plates were exposed to wortmannin (0.01, 0.1 m), TNF-␣ (5 ng/ml), or cAMP-dependent PKI (0.01, 0.1, 1 mg/ml) for 1 h. These samples were then incubated together with respective inhibitor plus insulin (10,000 U/ml) or glucagon (1.5 ϫ 10 
mRNA analysis
Cells were treated with insulin and glucagon alone and together, similar to the previous experiments. Total RNA was collected and mRNA analysis conducted using a probe for CaM as described previously (4).
Immunocytochemical staining
Cells were grown in RS-coated glass chamber slides (Nalge Nunc International, Naperville, IL). After achieving 60% confluency, cells were treated overnight (12-16 h) with serum-free media containing combinations of insulin, glucagon, and signaling pathway inhibitors as described in previous experiments. In these experiments, the cells had been treated for 24 h in serum-free media and then with hormone alone or hormone plus selected inhibitor overnight (12-14 h ). Concentrations of agents used were: insulin 10,000 U/ml; glucagon, 1.5 ϫ 10 Ϫ5 m; TNF-␣, 5 ng/ml; wortmannin, 1 m; and PKI, 10 g/ml. Cells were washed with PBS and immediately fixed with 10% neutralized formalin. Immunocytochemical staining was conducted with Sp1 antibody (11, 12) . Signal was developed by horseradish peroxidase conjugated second antibody employing 3,3Ј diaminobenzidine tetrahydrochloride-plus kit from Zymed Laboratories, Inc. (San Francisco, CA).
Statistical analysis
Bands in the x-ray films were scanned and quantified using the Quantity One software program from Bio-Rad Laboratories, Inc. in a Macintosh G-3 computer. Mean, sd, se, and t tests were calculated using the Excel program. These data were then grouped and analyzed statistically as shown.
Results

Effects of insulin and glucagon on Sp1
H-411E cells in culture were exposed to various doses of insulin for time intervals as indicated and cell extracts were analyzed by Western blotting. As shown in Fig. 1A , Sp1 levels were enhanced by insulin in a dose-dependent manner. Figure 1B illustrates a representative immunoblot showing that 10,000 U/ml insulin enhances steady-state levels of Sp1 in a time-dependent manner. Figure 1C demonstrates the cumulative quantitative analysis of Sp1 in response to insulin. The levels of Sp1 increase after insulin treatment, and peak at 4 h (P Ͻ 0.01).
Like insulin, glucagon stimulates Sp1 in a time-and dosedependent manner with time peak at 4 h, and dose peak at 1.5 ϫ 10 Ϫ5 m glucagon (data not shown). Data shown in Fig.  2A demonstrate that glucagon alone also stimulates Sp1, but not as strongly as insulin. Furthermore, when glucagon and insulin are present together, glucagon inhibits the enhancement of Sp1 possibly at lower concentrations of glucagon, but clearly at 1.5 ϫ 10 Ϫ5 m. The effect of glucagon alone on Sp1 was quantified from immunoblots and is graphically demonstrated in Fig. 2B , where glucagon alone stimulates Sp1 by approximately 100%, P Ͻ 0.002. In contrast, in Fig. 2C when insulin (10,000 U/ml) and glucagon (1.5 ϫ 10 Ϫ5 m) are incubated together in the cells, glucagon inhibits the effect of insulin on Sp1 by approximately 50%, P Ͻ 0.0002.
Effects of signal transduction inhibitors on Sp1
Wortmannin is an inhibitor of PI3K, thought to be the first signal in many of insulin's actions. Figure 3A (lower panel) illustrates the ability of wortmannin to inhibit insulin's stimulation of Sp1. In contrast, data in Fig. 3A (upper panel) demonstrate that glucagon stimulation of Sp1 is not inhibited by wortmannin. Figure 3B illustrates data from multiple experiments demonstrating that insulin stimulates Sp1 synthesis (P Ͻ 0.02 compared with basal) and wortmannin inhibits (P Ͻ 0.02) this effect. In Fig. 3 , A and B, glucagon alone also stimulates Sp1 (P Ͻ 0.001), but here wortmannin fails to Ϫ5 M alone and of glucagon ϩ insulin (Ins), 10,000 U/ml, together on Sp1 transcription factor extracted from H-411E cells in tissue culture as outlined in the text. Exposure is overnight (12-16 h) . A, Western blots of Glu (1.5 ϫ 10 Ϫ5 M) and Ins (10,000 U/ml) ϩ Glu at increasing concentration of (1.5 ϫ 10 Ϫ8 to 1.5 ϫ 10 Ϫ5 M). B and C, Densitometrically analyzed values of Western blots from multiple experiments, normalized to control. Number on the bar indicates the number of replicates. Values shown as mean Ϯ SEM. *, Statistical significance from control at given P value.
inhibit the enhanced accumulation of Sp1 in response to glucagon (glucagon vs. glucagon ϩ wortmannin, not significant).
TNF-␣ is known to antagonize the action of insulin in vitro and in vivo (13, 13a) . Our earlier findings that the enhanced expression of the CaM gene in response to insulin could be reversed by TNF-␣ are consistent with the proposed antagonism between TNF-␣ and insulin (4, 5) . Therefore, it was of interest to determine whether TNF-␣ altered the enhanced steady-state levels of Sp1 elicited by insulin and/or glucagon. A representative immunoblot to assess Sp1 levels in extracts of H-411E cells exposed to either insulin or glucagon in the absence or presence of TNF-␣ is shown in Fig. 4A . TNF-␣ treatment significantly inhibited the effect of insulin on Sp1 (Ins vs. con, P Ͻ 0.04; Ins vs. Ins ϩ TNF-␣, P Ͻ 0.04). In contrast, TNF-␣ had a negligible effect on Sp1 levels in glucagon-treated cells (Fig. 4A) . Quantification of Sp1 levels from multiple experiments (Fig. 4B) corroborated the visual data shown in Fig. 4A .
In light of the apparent distinction between the actions of insulin and glucagon revealed by TNF-␣, we sought to elucidate further mechanistic basis for these results. As depicted in Fig. 3 , the effect of insulin but not of glucagon on Sp1 could be abrogated by inhibitors of PI3K. Initially, we extended these data with inhibitors of cAMP, a second messenger needed for glucagon signaling. Our initial attempts to inhibit cAMP levels were equivocal at best (data not shown). Therefore, we tested a powerful inhibitor, cAMP-dependent PKI. Treatment of H-411E cells with PKI reduced the effect of glucagon but not that of insulin on Sp1 levels in a dose-dependent manner (data not shown). Quantification of these data indicate that 10 g/ml PKI inhibited glucagon-stimulated Sp1 levels by 45% (P Ͻ 0.03) (Fig. 5B) .
Immunocytochemical studies
Consistent with our published observations (8), immunoreactive Sp1 could be readily seen in the nuclei of the untreated control H-411E cells and treatment with insulin dramatically increased the nuclear staining intensity for Sp1 (Fig. 6, a and b) . Though, glucagon-stimulated cells (Fig. 6c ) demonstrated increased nuclear staining intensity for Sp1 antigens, as compared with control cells (Fig. 6a) , the increase was not as pronounced as in insulin-stimulated cells (Fig. 6b) . On a subjective scale, control cells were 2ϩ, glucagon stimulated cells 3ϩ, and insulin stimulated cells 4ϩ. It is worth pointing out at this stage, that the visible perception of staining intensity is logarithmic, therefore a 10-fold change is required to perceive a clear difference (11, 12) . We also observed a noticeable presence of Sp1 antigens in the cytoplasm of a small percentage (10%) of glucagon stimulated cells (Fig. 6, c and d) . The cytoplasmic staining for Sp1 in glucagon-treated cell cultures was highly reproducible and was rarely seen in H-411E cells stimulated with insulin.
Data shown in Fig. 7 demonstrate immunocytochemical staining of Sp1 antigens in H-411E cells after exposure to insulin or glucagon, in the presence of three known inhibitors of signal transduction, wortmannin, PKI, and TNF-␣. Insulin (Fig. 7, a1 ) and glucagon (Fig. 7, b1 ) both produced significant increases in Sp1 staining in cells (see Fig. 6 ) compared with control (Fig. 7, c1) . Wortmannin inhibited insulin-induced Sp1 staining significantly (Fig. 7, a2 ) but was less effective in blocking glucagoninduced Sp1 staining (Fig. 7, b2 ). In contrast, PKI, a cAMP inhibitor failed to inhibit insulin-induced Sp1 staining (Fig. 7, a3 ) but was very effective at inhibiting glucagoninduced Sp1 staining (Fig. 7, b3) . TNF-␣ not only markedly inhibited the stimulatory effects of insulin (Fig. 7, a4) and to a slightly lesser extent glucagon (Fig. 7, b4 ) but brought the Sp1 staining levels down, below those of control cells (Fig. 7, c1 ). When both insulin and glucagon are studied together (Fig. 7, c2) , glucagon inhibits insulin-stimulated Sp1 staining. Upper panels represent low magnification (ϫ80); lower panels depict higher magnification (ϫ600). a1, Cells exposed to insulin alone show the most intense nuclear staining of all the conditions tested. a2, Cells exposed to insulin and wortmannin (1 M); there is a clear decrease in the staining intensity as compared with insulin alone (a1). a3, Cells exposed to insulin and PKA inhibitor (10 g/ml); there is no clear effect on Sp1staining with all nuclei There is weak nuclear staining in all cells. Magnification, ϫ100. b, Insulin-treated cells. There is intense nuclear staining in all cells. The staining is strictly confined to the nucleus with only an occasional cell (Ͻ1%) demonstrating some cytoplasmic reactivity. Magnification, ϫ100. c, Glucagon-treated cells. There is increased nuclear staining in all cells, although of lesser intensity than in insulin treated cells. However, more than 10% of the cells have both nuclear as well as diffuse cytoplasmic staining (arrows). Magnification, ϫ100. d, Detail of glucagon-treated cells demonstrating both nuclear and cytoplasmic staining. Magnification, ϫ400.
remaining strongly positive. a4, Cells exposed to insulin and TNF-␣ (5 ng/ml); there is almost complete disappearance of any demonstrable Sp1 antigen. Therefore, in the absence of brown staining for Sp1, there is emergence of hematoxylin staining (blue). b1, Cells exposed to glucagon alone; although the staining intensity is less than in cells treated with insulin (a1), there is intense nuclear staining and occasional cytoplasmic staining. b2, Cells exposed to glucagon and wortmannin; there is no clear effect in nuclear or cytoplasmic staining intensity as compared with glucagon alone (b1). b3, Cells exposed to glucagon and PKA inhibitor; compared with glucagon alone (b1), there is a significant decrease in staining intensity. b4, Cells exposed to glucagon and TNF-␣; there is almost complete disappearance of demonstrable Sp1 antigen. The inhibition of the glucagon effect by TNF-␣ is present but weaker than the insulin effect (a4). c1, Cultured cells exposed to neither insulin nor glucagon have a less intense staining than those stimulated by either insulin or glucagon. c2, Cultured cells exposed to insulin and glucagon concomitantly show lower intensity of Sp1 staining compared with insulin alone (a1), demonstrating the antagonistic effects of these hormones.
Effects of insulin and glucagon on calmodulin mRNA synthesis
One of the effects of insulin is to significantly enhance rates of calmodulin gene transcription that are mediated by Sp1 (4, 5) . Consistent with previous observations, data shown in Table 1 demonstrate that insulin stimulates CaM gene expression (ϩ70% for insulin). However, treatment with glucagon did not significantly effect the steady-state levels of CaM mRNA (Table 1) . In contrast to this, glucagon was effective in neutralizing the insulin-mediated enhanced transcription of the CaM gene ( Table 1) .
Effects of insulin and glucagon on glycosylation of Sp1
Both insulin and glucagon stimulated the steady-state levels of total Sp1 in H-411E cells (Fig. 8A) . Because additional levels of regulation may be exerted by preferentially glycosylating Sp1, we tested if the levels of O-GlcNAc-modified Sp1 were altered by either insulin and/or glucagon. Data shown in Fig. 8 illustrate Western blots of cell extracts after exposure to insulin or glucagon for 4 h. An aliquot of extracts was immunoblotted and probed with antibodies directed against Sp1 (8A). To assess the equivalence of protein loading, membranes were probed with antibodies to ␤-actin.
Parallel aliquots of 500 g of the total cellular protein from each treatment were immunoprecipitated with Sp1 antibody, immunoblotted, and probed with anti O-GlcNAc antibody to detect glycosylated Sp1 (8B). Insulin and glucagon both stimulated the steady-state levels of Sp1 protein. However, after insulin exposure, the glycosylated Sp1 was markedly increased, whereas glucagon-treated cells exhibited almost no difference in glycosylated Sp1 from untreated controls. The overall effect of insulin and glucagon on the levels of Sp1 were probed in the blots after stripping the GlcNAc antibodies and were similar to what was observed in the whole cell extracts (data not shown).
Discussion
Sp1, the best characterized member of the Sp transcription factor family (14) , is critical for both basal and insulin-stimulated CaM gene transcription (6, 7) . Present studies demonstrate a dose and time dependency for insulin stimulation of Sp1. Because of a close but usually antagonistic relationship between insulin and glucagon, we investigated the effect of the latter hormone on Sp1. To our surprise, similar to insulin, glucagon alone stimulated accumulation of Sp1. However, when added together, glucagon totally inhibited insulin's stimulatory effect on Sp1. To some extent this may reflect, what we see clinically; insulin lowers blood glucose, glucagon raises it and insulin deficiency or glucagon excess, lead to diabetes mellitus, i.e. insulin and glucagon act antagonistically toward each other in physiological settings (9, 10) . This anabolic/catabolic switch may have common effector pathways. Tang et al. (15) propose a mechanism of repressive activity of Sp1 in the C/EBP␣ promoter that is activated during adipocyte differentiation. Ahlgren et al. (16) show evidence of positive impact of Sp1 transcription factor on activity of cAMP-dependent bovine CYPIIA gene. Several genes have Sp1 binding sites within the broadly defined cis-acting module encompassing cAMP responsive elements of their promoters. Thus, modulation of metabolic activities and gene expression by both insulin and glucagon may be mediated by common transcription factors that bind to cAMP-responsive and GC-rich elements.
To examine the mechanism of antagonism between these two hormones, we chose specific inhibitors known to affect pathways important to either insulin or glucagon action. Wortmannin, an inhibitor of PI3K and an important second messenger for many of insulin's actions (17, 18) , markedly reduced insulin-stimulated Sp1 synthesis but had no effect on glucagon stimulation of Sp1. This is consistent with PI3K activity being a key factor in the signaling pathway for insulin (3). Several other insulin-stimulated activities are blocked by wortmannin, i.e. glucose transport (17, 19) and down-regulation of gene expression of CYP2E1 (20) . However, modulation of these effects by interaction between PI3K signaling and/or Sp1 has not yet been critically examined. We demonstrate an essential role of PI3K in induction of transcription via Sp1. Another important antagonist of insulin is the cytokine TNF-␣ (13) . TNF-␣ is thought to work by phosphorylating serine on the insulin receptor substrate 1 (IRS-1) protein, thereby preventing insulin from stimulating its receptor to phosphorylate tyrosine on IRS-1 and ini- Densitometric quantitation of autoradiographs of Northern blots for CaM mRNA in H-411 E cells exposed to insulin and glucagon. The data from three independent experiments are shown. Data are normalized to control (100%). Please see Materials and Methods in text for further details.
tiating its own signal (13, 13a, 21) . TNF-␣ clearly abolished insulin-stimulated Sp1 synthesis in H-411E cells. TNF-␣ also inhibits Sp1 synthesis (8) and CaM gene transcription (21) . However, TNF-␣ did not inhibit Sp1 synthesis stimulated by glucagon on the Western blot. This was predictable because glucagon is thought to initiate most or all of its effects through cAMP, so inhibition of IRS-1 that is not tied to the cAMP pathway should not affect glucagon. The opposing effects of insulin and glucagon may reflect opposing actions of these hormones on apoptosis, with insulin being antiapoptotic (lowering cAMP) and glucagon and TNF-␣ (raising cAMP) promoting apoptosis. However, we have not directly investigated the potential action of these hormones on H-411E cell survival and its relationship to Sp1 biogenesis and accumulation.
Could we define the pathway that mediated glucagon's stimulation of Sp1 and ultimately transcription of multiple genes? We initially tried some inhibitors of cAMP synthesis but results were equivocal at best. However, PKI, a powerful inhibitor of cAMP, unequivocally inhibited glucagon-stimulation of Sp1 in a dose-dependent manner. It was reported earlier that PKI could abolish glucagon's stimulatory effect on transcription of CYP2E1 gene (20) .
We also performed immunocytochemical staining of the H-411E cells using anti-Sp1 antibody, after treatment with insulin, glucagon, or both together. Previous data from our laboratory have shown Sp1 staining in the nucleus, clearly intensified by insulin, and inhibited by TNF-␣ (8). As judged by immunocytochemical staining, both insulin and glucagon-stimulated Sp1 accumulation in the H-411E cell nuclei. However, in contrast to insulin 10 -15% of the glucagonexposed cells have demonstrable Sp1 antigens in the cytoplasm as well as the nucleus. Because the Sp1 protein is synthesized in the endoplasmic reticulum, it would seem that in a subset of cells glucagon prevents or delays its migration to the nucleus. Perhaps this could reflect the extent of either phosphorylation or glycosylation of Sp1 (22-26, 28, 29) , influencing subcellular localization. Alternatively, it could also be due to differences in the rate of accumulation of Sp1 in subcellular compartments at different stages of the cell cycle. TNF-␣ clearly inhibited Sp1 staining induced by insulin (Fig. 7) , but this diminution in staining for Sp1 was also seen to a lesser extent with glucagon and TNF-␣ (Fig. 7) . The former effect (insulin) was anticipated; the latter (glucagon) was not, as it does not match with our Western blot (Fig. 4) or our presumptive understanding of mechanisms, involved. TNF-␣ inhibition of glucagon stimulated Sp1 seen here could be secondary to its previously reported ability to inhibit cAMP (27) . Additional immunocytochemical studies seen in Fig. 7 are in concordance with the Western blot data with a few exceptions. The differences in the time of exposure of cells to TNF-␣ for immunostaining (12-16 h) and Western blotting (4 h), may partially be responsible for the apparent discrepancy between the two data. Because O-glycosylation of Sp1, which occurs with insulin but not glucagon, likely alters its susceptibility to degradation, the initial increase in glucagon-stimulated Sp1 at 4 h seen by Western blotting may be significantly weakened due to degradation during the 12-to 16-h incubation for immunostaining. This would be even more likely, if TNF-␣ itself inhibits glycosylation or otherwise promotes Sp1 degradation directly. To examine further these and other differences between insulin and glucagon stimulation of Sp1 and possible compartmentalization, transport or migration differences between cytoplasmic structures, nucleus, etc., we studied the glycosylation state of the Sp1. Data presented in Fig. 8 provide strong preliminary support for a role for O-glycosylation of Sp1 in translating the effects of insulin and glucagon. In cells treated with insulin alone, Sp1 is most probably hyperglycosylated and translocates to the nucleus and facilitates transcription more efficiently (25, 28, 29) . In cells treated with glucagon alone, Sp1 is probably in a hypoglycosylated form, which can mean: 1) the hypoglycosylation marks the Sp1 for proteosomic degradation; 2) the hypoglycosylated Sp1 may not yet be properly folded into its final quaternary structure (25) ; and 3) the hypoglycosylated Sp1 is not functioning and gives an unclear defective translocation signal. Because insulin stimulates both glycosylation and nuclear staining of Sp1 and enhances transcription of a Sp1-driven CaM promoter, it is more potent than glucagon, which does not glycosylate the Sp1, and, hence, leaves it less active in the cytoplasm unable to migrate to the nucleus.
Sp1 is able to regulate the synthesis of many new proteins. To extend the above observations to the next level, we performed Northern blots of H-411E cells exposed to insulin or glucagon. Consistent with our previously published data (4, 5) , our data in Table 1 again demonstrate that insulin stimulates CaM gene expression, but, as can be seen, glucagon does not. With CaM gene transcription clearly linked to insulin's stimulation of Sp1, why did another hormone, i.e. glucagon which also stimulates Sp1, not affect CaM gene transcription? As outlined above, these differences could be due to differences in signal transduction, subcellular compartmentalization, phosphorylation, or more likely glycosylation. Future investigations will be needed to explain the cause of these differences, i.e. transcription vs. translation. However, it is not far-fetched to suppose that the insulin/ glucagon ratio, which is a critical factor in homeostasis and maintenance of blood glucose and multiple metabolic parameters (ketosis, lipolysis, etc.), also regulates selective gene transcription, orchestrating the net response to reflect the insulin/glucagon ratio. In this way, along with selective compartmentalization, glycosylation and/or phosphorylation and use of multiple signal transduction pathways, the appropriate cellular response to physiologic or pathologic challenges can be orchestrated.
